Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MPO | P05164 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | KDM5A | P29375 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | OGG1 | O15527 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566508 | 0.84 | MPO (0.53) | KDM4ELMNAMAPTALDH1A1L3MBTL1 | |
| SCHEMBL24609542 | 0.82 | RAB9A (0.59) | KDM4ELMNAMAPTALDH1A1BLM | |
| SCHEMBL23782630 | 0.82 | MPO (0.52) | KDM4ELMNAMAPTALDH1A1L3MBTL1 | |
| SCHEMBL2678949 | 0.82 | MPO (0.80) | KDM4ELMNAMAPTALDH1A1L3MBTL1 | |
| SCHEMBL343630 | 0.82 | MPO (0.80) | KDM4ELMNAMAPTALDH1A1L3MBTL1 | |
| SCHEMBL105171 | 0.81 | HDAC6 (0.59) | KDM4ELMNARAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5943921 | 0.81 | HDAC6 (0.71) | RAB9ASMN1; SMN2MEN1KMT2ACA1 | |
| SCHEMBL28960899 | 0.80 | HDAC1 (0.55) | KDM4ELMNAMAPTALDH1A1L3MBTL1 | |
| SCHEMBL12069255 | 0.80 | SCN5A (0.59) | KDM4ELMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL104304 | 0.80 | RAB9A (0.61) | KDM4ELMNAMAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059189-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-02-20 | — | — | US | disclosed |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-12054486-B2 | Pyridine derivatives and their use as sodium channel activators | XENON PHARMACEUTICALS INC. (CA) | 2024-08-06 | — | — | US | disclosed |
| EP-4405347-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | Xenon Pharmaceuticals Inc. (CA) | 2024-07-31 | — | — | EP | disclosed |
| CN-118284602-A | Pyridine derivatives as sodium channel activators and uses thereof | 泽农医药公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240139214-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2024-05-02 | — | — | US | disclosed |
| EP-4289422-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Kyushu University, National University Corporation (JP) | 2023-12-13 | — | — | EP | disclosed |
| CN-117042759-A | IL-31 production inhibitor and pharmaceutical composition containing the same | 国立大学法人九州大学 | 2023-11-10 | — | — | CN | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | SAINT LOUIS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| EP-2311455-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301536-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301538-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1815206-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044456-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| US-20030158237-A1 | Combination of antioxidant substances for the treatment of alzheimer's disease | COLBA R & D INC. (CA) | 2003-08-21 | — | — | US | disclosed |
| US-4017540-A | INSECTICIDES, MITICIDES | THE UPJOHN COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-3932661-A | Anthelmintic methods employing benzoyl chloride phenylhydrazones | THE UPJOHN COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | P2RY14, P2RY4, P2RY13 | KDM4E 4599/4885LMNA 3507/4885MAPT 3757/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | KDM4E 1330/4885LMNA 4729/4885MAPT 277/4885 |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | KDM4E 1227/4885LMNA 751/4885MAPT 3781/4885 |
| US-20240139214-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | IL36G, IL1RN, IL1B | KDM4E 2781/4885LMNA 4301/4885MAPT 3812/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | KDM4E 2139/4885LMNA 2275/4885MAPT 569/4885 |
| US-12054486-B2 | Pyridine derivatives and their use as sodium channel activators | SCN1A, SCN1B, CACNA1A | KDM4E 1263/4885LMNA 1089/4885MAPT 231/4885 |
| US-20250059189-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN1B, CACNA1A | KDM4E 1253/4885LMNA 1000/4885MAPT 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.